BioTuesdays

Category - Markets

GlycoMimetics
Markets

Stifel ups GlycoMimetics price target to $23

Stifel raised its price target for GlycoMimetics (NASDAQ:GLYC) to $23 from $17 after the company presented incremental Phase 1/2 data for GMI-1271 in both relapsed/refractory (R/R) and newly-diagnosed AML patients. The...

December 12, 2017
scPharmaceuticals
Markets

Leerink starts scPharmaceuticals at OP; PT $20

Leerink launched coverage of scPharmaceuticals (NASDAQ:SCPH) with an “outperform” rating and $20 price target. The stock closed at $14.92 on Dec 11. “The lead product, Furoscix (furosemide, diuresis for heart failure...

December 12, 2017
Diplomat Pharmacy
Markets

Leerink ups Diplomat Pharmacy to OP; PT to $23

Leerink upgraded Diplomat Pharmacy (NYSE:DPLO) to “outperform” and raised its price target to $23 from $20 after recent investor meetings with the company’s management and after considering several new developments. The...

December 11, 2017
Akebia Therapeutics Logo
Markets

BTIG starts Akebia Therapeutics at buy; PT $30

BTIG initiated coverage of Akebia Therapeutics (NASDAQ:AKBA) with a “buy” rating and price target of $30. The stock closed at $15.40 on Dec. 6. Akebia is focused on the development of Vadadustat, a novel oral, once...

December 7, 2017
inflaRx
Markets

Leerink starts InflaRx at outperform; PT $31

Leerink initiated coverage of InflaRx N.V. (NASDAQ:IFRX) with an “outperform” rating and $31 price target. The stock closed at $20.88 on Dec. 1. “InflaRx has an opportunity to generate significant shareholder value with...

December 4, 2017
Madrigal Pharmaceuticals
Markets

Roth ups Madrigal Pharma PT to $82

Roth Capital Partners raised its price target for Madrigal Pharmaceuticals (NASDAQ:MDGL) to $82 from $62 ahead of interim results in late December from the company’s Phase 2b NASH trial. Nonalcoholic steatohepatitis...

December 1, 2017
Verastem
Markets

Roth starts Verastem at buy; PT $12

Roth Capital Partners launched coverage of Verastem (NASDAQ:VSTM) with a “buy” rating and $12 price target. The stock closed at $3.66 on Nov. 29. Analyst Dr. Jotin Marango writes that his qualitative and quantitative...

November 30, 2017
Arcturus Logo
Markets

Ladenburg starts Arcturus at buy; PT $22

Ladenburg Thalmann initiated coverage of Arcturus Therapeutics (NASDAQ:ARCT) with a “buy” rating and $22 share price target. The stock closed at $8.71 on Nov. 28. Arcturus has developed a novel biodegradable lipid...

November 29, 2017
Viking Therapeutics Logo
Markets

Maxim ups Viking Therapeutics PT to $8

Maxim Group raised its price target for Viking Therapeutics (NASDAQ:VKTX) to $8 from $5 after the company announced results of a Phase 2 hip fracture study of its VK5211 compound. The stock was changing hands at $3.07...

November 28, 2017
Spero Therapeutics
Markets

Stifel starts Spero Therapeutics at buy; PT $26

Stifel initiated coverage of Spero Therapeutics (NASDAQ:SPRO) with a “buy” rating and $26 price target. The stock closed at $13.86 on Nov. 24. “We believe Spero’s wholly-owned product pipeline of novel antibiotics –...

November 27, 2017